Bauss F - Search Results

1

Daily or monthly ibandronate prevents or restores deteriorations of bone mass, architecture, biomechanical properties and markers of bone turnover in androgen-deficient aged rats.

De La Piedra C, Quiroga I, Montero M, Dapia S, Caeiro JR, Rubert M, Diaz-Curiel M, Bauss F. De La Piedra C, et al. Among authors: bauss f. Aging Male. 2011 Dec;14(4):220-30. doi: 10.3109/13685538.2010.518176. Epub 2010 Oct 12. Aging Male. 2011. PMID: 20937008 Free article.

2

Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats.

Bauss F, Lalla S, Endele R, Hothorn LA. Bauss F, et al. J Rheumatol. 2002 Oct;29(10):2200-8. J Rheumatol. 2002. PMID: 12375334

3

Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats.

Bauss F, Wagner M, Hothorn LH. Bauss F, et al. J Rheumatol. 2002 May;29(5):990-8. J Rheumatol. 2002. PMID: 12022363

4

Effects of ibandronate on bone quality: preclinical studies.

Bauss F, Dempster DW. Bauss F, et al. Bone. 2007 Feb;40(2):265-73. doi: 10.1016/j.bone.2006.08.002. Epub 2006 Sep 22. Bone. 2007. PMID: 16996333 Review.

5

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.

Schimmer RC, Bauss F. Schimmer RC, et al. Among authors: bauss f. Clin Ther. 2003 Jan;25(1):19-34. doi: 10.1016/s0149-2918(03)90005-1. Clin Ther. 2003. PMID: 12637110 Review.

6

Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.

Smith SY, Recker RR, Hannan M, Müller R, Bauss F. Smith SY, et al. Among authors: bauss f. Bone. 2003 Jan;32(1):45-55. doi: 10.1016/s8756-3282(02)00923-7. Bone. 2003. PMID: 12584035

7

Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats.

Lalla S, Hothorn LA, Haag N, Bader R, Bauss F. Lalla S, et al. Among authors: bauss f. Osteoporos Int. 1998;8(2):97-103. doi: 10.1007/BF02672503. Osteoporos Int. 1998. PMID: 9666930

8

Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties.

Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH. Monier-Faugere MC, et al. Among authors: bauss f. J Bone Miner Res. 1999 Oct;14(10):1768-78. doi: 10.1359/jbmr.1999.14.10.1768. J Bone Miner Res. 1999. PMID: 10491225 Free article.

9

Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs.

Glüer CC, Scholz-Ahrens KE, Helfenstein A, Delling G, Timm W, Açil Y, Barkmann R, Hassenpflug J, Stampa B, Bauss F, Schrezenmeir J. Glüer CC, et al. Among authors: bauss f. Bone. 2007 Mar;40(3):645-55. doi: 10.1016/j.bone.2006.10.019. Epub 2006 Dec 15. Bone. 2007. PMID: 17174621

10

The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats.

Kurth AH, Eberhardt C, Müller S, Steinacker M, Schwarz M, Bauss F. Kurth AH, et al. Among authors: bauss f. Bone. 2005 Aug;37(2):204-10. doi: 10.1016/j.bone.2004.12.017. Bone. 2005. PMID: 15936997

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters